Advice
Following a re-submission.
Ropinirole (Adartrel) is accepted for restricted use within NHS Scotland for the treatment of moderate to severe idiopathic restless legs syndrome (RLS).Its use should be restricted to patients with a baseline score of 24 points or more on the International Restless Legs Scale (IRLS).
Compared with placebo, ropinirole was associated with a 4-point improvement on the 40- point IRLS in a pooled analysis restricted to patients with IRLS score of 24 points.
Download detailed advice42KB (PDF)
Medicine details
- Medicine name:
- ropinirole tablets (Adartrel)
- SMC ID:
- 165/05
- Indication:
- Moderate to severe idiopathic restless legs syndrome
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 10 July 2006